Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Accumulated Depreciation (2021 - 2024)

Kezar Life Sciences (KZR) has disclosed Accumulated Depreciation for 4 consecutive years, with $6.2 million as the latest value for Q3 2024.

  • Quarterly Accumulated Depreciation rose 20.64% to $6.2 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Sep 2024, up 20.64% year-over-year, with the annual reading at $5.4 million for FY2023, 17.77% up from the prior year.
  • Accumulated Depreciation hit $6.2 million in Q3 2024 for Kezar Life Sciences, up from $5.9 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $6.2 million in Q3 2024 to a low of $3.0 million in Q1 2021.
  • Historically, Accumulated Depreciation has averaged $4.6 million across 4 years, with a median of $4.6 million in 2022.
  • Biggest five-year swings in Accumulated Depreciation: skyrocketed 31.25% in 2022 and later increased 16.42% in 2023.
  • Year by year, Accumulated Depreciation stood at $3.7 million in 2021, then grew by 26.01% to $4.6 million in 2022, then rose by 17.77% to $5.4 million in 2023, then grew by 14.41% to $6.2 million in 2024.
  • Business Quant data shows Accumulated Depreciation for KZR at $6.2 million in Q3 2024, $5.9 million in Q2 2024, and $5.7 million in Q1 2024.